Difference between revisions of "SMARCB1"

From Libre Pathology
Jump to navigation Jump to search
 
Line 32: Line 32:
==See also==
==See also==
*[[Immunohistochemistry]].
*[[Immunohistochemistry]].
*[[SMARCA4]].
*[[SMARCA4-deficient adenocarcinoma of the lung]].
*[[SMARCA4-deficient adenocarcinoma of the lung]].



Latest revision as of 00:57, 27 December 2023

SMARCB1
Immunostain in short

INI1-ve in AT/RT.
Abbreviation SMARCB1, BAF47
Normal staining pattern nuclear staining
Positive any healthy tissue
Negative AT/RT, renal rhabdoid tumour, extrarenal malignant rhabdoid tumour, atypical teratoid/rhabdoid tumour, epithelioid sarcoma

SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily B, member 1, commonly abbreviated SMARCB1, is a diagnostic immunostain, because nuclear staining is lost in some specific types of cancer shown below.

It is also known as INI1, INI-1 and BAF47.

Negative

See also

References

  1. Hornick, Jason (2009). "Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma". American Journal of Surgical Pathology.
  2. Jackson EM, Sievert AJ, Gai X et al. (March 2009). "Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors". Clin. Cancer Res. 15 (6): 1923–30.
  3. Bishop, JA.; Antonescu, CR.; Westra, WH. (Sep 2014). "SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract.". Am J Surg Pathol 38 (9): 1282-9. doi:10.1097/PAS.0000000000000285. PMID 25007146.
  4. Hasselblatt, M.; Isken, S.; Linge, A.; Eikmeier, K.; Jeibmann, A.; Oyen, F.; Nagel, I.; Richter, J. et al. (Feb 2013). "High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors.". Genes Chromosomes Cancer 52 (2): 185-90. doi:10.1002/gcc.22018. PMID 23074045.
  5. Mularz, K.; Harazin-Lechowska, A.; Ambicka, A.; Kruczak, A.; Rozmus-Piętoń, M.; Marchińska-Osika, U.; Swiątkiewicz, I.; Król, M. et al. (Nov 2012). "Specificity and sensitivity of INI-1 labeling in epithelioid sarcoma. Loss of INI1 expression as a frequent immunohistochemical event in synovial sarcoma.". Pol J Pathol 63 (3): 179-83. PMID 23161234.
  6. Agaimy A, Hartmann A (November 2021). "[SMARCB1(INI1)-deficient renal cell carcinoma: medullary and beyond : Evolving concepts]" (in German). Pathologe 42 (6): 571–577. doi:10.1007/s00292-021-00985-y. PMID 34609565.
  7. Agaimy A, Rau TT, Hartmann A, Stoehr R (July 2014). "SMARCB1 (INI1)-negative rhabdoid carcinomas of the gastrointestinal tract: clinicopathologic and molecular study of a highly aggressive variant with literature review". Am J Surg Pathol 38 (7): 910–20. doi:10.1097/PAS.0000000000000173. PMID 24503755.